CA3087652A1 - Selective parp1 inhibitors to treat cancer - Google Patents

Selective parp1 inhibitors to treat cancer Download PDF

Info

Publication number
CA3087652A1
CA3087652A1 CA3087652A CA3087652A CA3087652A1 CA 3087652 A1 CA3087652 A1 CA 3087652A1 CA 3087652 A CA3087652 A CA 3087652A CA 3087652 A CA3087652 A CA 3087652A CA 3087652 A1 CA3087652 A1 CA 3087652A1
Authority
CA
Canada
Prior art keywords
inhibitor
cancer
use according
parp1
selective inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3087652A
Other languages
English (en)
French (fr)
Inventor
Melinda DUER
David Reid
Uliana BASHTANOVA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cambridge Enterprise Ltd
Original Assignee
Cambridge Enterprise Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Enterprise Ltd filed Critical Cambridge Enterprise Ltd
Publication of CA3087652A1 publication Critical patent/CA3087652A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3087652A 2018-01-17 2019-01-16 Selective parp1 inhibitors to treat cancer Pending CA3087652A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1800733.6 2018-01-17
GBGB1800733.6A GB201800733D0 (en) 2018-01-17 2018-01-17 Cancer
PCT/GB2019/050110 WO2019141979A1 (en) 2018-01-17 2019-01-16 Selective parp1 inhibitors to treat cancer

Publications (1)

Publication Number Publication Date
CA3087652A1 true CA3087652A1 (en) 2019-07-25

Family

ID=61256175

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3087652A Pending CA3087652A1 (en) 2018-01-17 2019-01-16 Selective parp1 inhibitors to treat cancer

Country Status (7)

Country Link
US (1) US20210052632A1 (https=)
EP (1) EP3740238A1 (https=)
JP (1) JP7364154B2 (https=)
CN (1) CN111629757A (https=)
CA (1) CA3087652A1 (https=)
GB (1) GB201800733D0 (https=)
WO (1) WO2019141979A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2592555A (en) * 2019-09-27 2021-09-08 Varsity Pharmaceuticals Ltd Cancer
AU2022334408A1 (en) * 2021-08-27 2024-02-15 Impact Therapeutics (Shanghai), Inc. Substituted tricyclic compounds as parp inhibitors and use thereof
IL314895A (en) * 2022-02-16 2024-10-01 Duke Street Bio Ltd Pharmaceutical compound
US20250352539A1 (en) * 2022-06-15 2025-11-20 Astrazeneca Ab Combination therapy for treating cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008144067A1 (en) * 2007-05-21 2008-11-27 Board Of Regents, University Of Texas System Methods and compositions for treatment of cancer using oncolytic rsv activity
US20110190390A1 (en) * 2010-01-05 2011-08-04 Nicole Renee Murray Methods and materials for treating pancreatic cancer
EP3052655B1 (en) * 2013-09-30 2018-11-07 Institute For Cancer Research D/b/a The Research Institute of Fox Chase Cancer Center Closantel in combination with temozolomide for use in the treatment of a cancer in which is thymine dna glycosylase expressed
KR20180132939A (ko) * 2016-05-03 2018-12-12 갈레라 랩스, 엘엘씨 암 치료를 위한 조합 요법
GB2592555A (en) * 2019-09-27 2021-09-08 Varsity Pharmaceuticals Ltd Cancer

Also Published As

Publication number Publication date
US20210052632A1 (en) 2021-02-25
JP7364154B2 (ja) 2023-10-18
GB201800733D0 (en) 2018-02-28
EP3740238A1 (en) 2020-11-25
CN111629757A (zh) 2020-09-04
WO2019141979A1 (en) 2019-07-25
JP2021510677A (ja) 2021-04-30

Similar Documents

Publication Publication Date Title
CN1681495B (zh) 用于治疗过度增生性疾病的组合物
CA3087652A1 (en) Selective parp1 inhibitors to treat cancer
TWI607754B (zh) 醫藥組合
CN100591331C (zh) 联合化疗组合物
US8507555B2 (en) Non-toxic anti-cancer drug combining ascorbate, magnesium and a naphthoquinone
KR20230118147A (ko) 전립선암 치료 방법
US20090035315A1 (en) Method of Improving Treatments in Rheumatic and Arthritic Diseases
RS66424B1 (sr) Kombinovane terapije
EP2968379B1 (en) Etoposide prodrugs for use in targeting cancer stem cells
CA3110609C (en) 5-acetamidomethyl-oxazolidinone derivatives for use in the treatment of cancer
EP3429572B1 (en) Combination therapy for proliferative diseases
WO2021163273A1 (en) Uses of glucocorticoid receptor antagonists
EP3852741A1 (en) Combination of gold complexes with olaparib or other parp1/2 inhibitors for use in the treatment of cancer resistant to said parp1/2 inhibitors
KR102644045B1 (ko) 신규한 소분자 화합물
US20230226090A1 (en) Treatments of prostate cancer
WO2024064883A2 (en) Therapeutic combinations comprising ubiquitin-specific-processing protease 1 (usp1) inhibitors and parp1-selective inhibitors
ES3052451T3 (en) Methods of treating cancer using hsf1 pathway inhibitors
US9278924B2 (en) 5-nonyloxytryptamine and related intracellular PH acidifiers for the treatment and prevention of cancer
KR101933805B1 (ko) 옥셀라딘시트레이트를 유효성분으로 포함하는 뇌암 예방 또는 치료용 약학적 조성물
TW201420102A (zh) 組合療法
HK40100586A (en) Csf1r inhibitors for use in treating tenosynovial giant cell tumors
WO2024167856A1 (en) Method for treating nervous system disorders using boldine and analogs thereof
HK1236134B (en) Pharmaceutical combination comprising a cdk inhibitor and a thioredoxin reductase inhibitor for the treatment of cancer
HK1220365B (en) Etoposide prodrugs for use in targeting cancer stem cells

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210426